[HTML][HTML] Cerebrospinal fluid proteomics in patients with Alzheimer's disease reveals five molecular subtypes with distinct genetic risk profiles
BM Tijms, EM Vromen, O Mjaavatten, H Holstege… - Nature aging, 2024 - nature.com
Alzheimer's disease (AD) is heterogenous at the molecular level. Understanding this
heterogeneity is critical for AD drug development. Here we define AD molecular subtypes …
heterogeneity is critical for AD drug development. Here we define AD molecular subtypes …
[PDF][PDF] Cerebrospinal fluid proteomics in patients with Alzheimer's disease reveals five molecular subtypes with distinct genetic risk profiles
BM Tijms, EM Vromen, O Mjaavatten, H Holstege… - pure.tudelft.nl
Alzheimer's disease (AD) is heterogenous at the molecular level. Understanding this
heterogeneity is critical for AD drug development. Here we define AD molecular subtypes …
heterogeneity is critical for AD drug development. Here we define AD molecular subtypes …
Cerebrospinal fluid proteomics in patients with Alzheimer's disease reveals five molecular subtypes with distinct genetic risk profiles
BM Tijms, EM Vromen, O Mjaavatten, H Holstege… - Nature …, 2024 - discovery.ucl.ac.uk
Alzheimer's disease (AD) is heterogenous at the molecular level. Understanding this
heterogeneity is critical for AD drug development. Here we define AD molecular subtypes …
heterogeneity is critical for AD drug development. Here we define AD molecular subtypes …
Cerebrospinal fluid proteomics in patients with Alzheimer's disease reveals five molecular subtypes with distinct genetic risk profiles.
BM Tijms, EM Vromen, O Mjaavatten, H Holstege… - Nature …, 2024 - europepmc.org
Alzheimer's disease (AD) is heterogenous at the molecular level. Understanding this
heterogeneity is critical for AD drug development. Here we define AD molecular subtypes …
heterogeneity is critical for AD drug development. Here we define AD molecular subtypes …
Cerebrospinal fluid proteomics in patients with Alzheimer's disease reveals five molecular subtypes with distinct genetic risk profiles
BM Tijms, EM Vromen, O Mjaavatten… - Nature …, 2024 - researchinformation.amsterdamumc …
Alzheimer's disease (AD) is heterogenous at the molecular level. Understanding this
heterogeneity is critical for AD drug development. Here we define AD molecular subtypes …
heterogeneity is critical for AD drug development. Here we define AD molecular subtypes …
Cerebrospinal fluid proteomics in patients with Alzheimer's disease reveals five molecular subtypes with distinct genetic risk profiles
BM Tijms, EM Vromen, O Mjaavatten, H Holstege… - Nature …, 2024 - repository.tudelft.nl
Alzheimer's disease (AD) is heterogenous at the molecular level. Understanding this
heterogeneity is critical for AD drug development. Here we define AD molecular subtypes …
heterogeneity is critical for AD drug development. Here we define AD molecular subtypes …
[引用][C] Cerebrospinal fluid proteomics in patients with Alzheimer's disease reveals five molecular subtypes with distinct genetic risk profiles
BM Tijms - Nature Aging, 2024 - pure.knaw.nl
Cerebrospinal fluid proteomics in patients with Alzheimer’s disease reveals five molecular
subtypes with distinct genetic risk profiles — Royal Netherlands Academy of Arts and Sciences …
subtypes with distinct genetic risk profiles — Royal Netherlands Academy of Arts and Sciences …
Cerebrospinal fluid proteomics in patients with Alzheimer's disease reveals five molecular subtypes with distinct genetic risk profiles
BM Tijms, EM Vromen, O Mjaavatten… - Nature …, 2024 - pubmed.ncbi.nlm.nih.gov
Alzheimer's disease (AD) is heterogenous at the molecular level. Understanding this
heterogeneity is critical for AD drug development. Here we define AD molecular subtypes …
heterogeneity is critical for AD drug development. Here we define AD molecular subtypes …
Cerebrospinal fluid proteomics in patients with Alzheimer's disease reveals five molecular subtypes with distinct genetic risk profiles
BM Tijms, EM Vromen, O Mjaavatten… - Nature …, 2024 - cris.maastrichtuniversity.nl
Alzheimer's disease (AD) is heterogenous at the molecular level. Understanding this
heterogeneity is critical for AD drug development. Here we define AD molecular subtypes …
heterogeneity is critical for AD drug development. Here we define AD molecular subtypes …
Cerebrospinal fluid proteomics in patients with Alzheimer's disease reveals five molecular subtypes with distinct genetic risk profiles
BM Tijms, EM Vromen, O Mjaavatten, H Holstege… - Nature …, 2024 - research.tudelft.nl
Alzheimer's disease (AD) is heterogenous at the molecular level. Understanding this
heterogeneity is critical for AD drug development. Here we define AD molecular subtypes …
heterogeneity is critical for AD drug development. Here we define AD molecular subtypes …